Ticker

TC Energy is upgraded from 'Hold' to 'Buy' based on robust Q2 results and a clear growth outlook. TRP delivered 12% YoY comparable EBITDA growth, driven by high utilization across the U.S., Mexico, and power segments. It maintains a BBB+ credit rating, 4.75x debt/EBITDA, and a 3.8% yield, supporting continued dividend growth.

Procter & Gamble is trading near its 52-week low, offering a 3% dividend yield and a forward P/E of 20.6x, below its 10-year average. PG demonstrates resilient earnings, a strong brand portfolio, and innovation-led growth, especially in China and Latin America, despite recent consumer demand headwinds. AI-driven innovation and supply chain upgrades position the company for EPS growth and improved productivity, with…

Hormel is reaffirmed as a "Buy" for its resilient organic growth, margin expansion, and defensive income profile. HRL delivered 3% YoY organic sales growth and 14% adjusted EPS growth in Q2, outperforming the S&P 500 year-to-date. Operational improvements, a strong balance sheet, and a 4.6% dividend yield support the investment case at a 17.3x forward P/E.

Passive income has a way of quieting the noise. Whether markets are grinding higher, correcting hard, or drifting sideways, a dividend check lands in your account on the schedule the company sets, regardless of what the stock is doing.

Abbott Laboratories (NYSE:ABT | ABT Price Prediction) is a stock with characteristics suited to multi-decade ownership, because its four-segment healthcare engine, 54 consecutive years of dividend increases, and recession-resistant end markets give a retirement-focused portfolio something rare: cash compounding that does not require monitoring.